VitaLink Research Selected Pivotal COVID-19 Vaccine Phase 3 Clinical Trial

VitaLink Research Selected Pivotal COVID-19 Vaccine Phase 3 Clinical Trial

VitaLink Research in Greenville, South Carolina, was selected by Moderna to run its pivotal Phase III mRNA-1273 COVID-19 vaccine clinical trial. VitaLink reports that this clinical investigational site targets 1,500 (5%) of the total study participants. COVID-19 has hit South Carolina relatively hard, with 25,701 and 659 deaths.

VitaLink Research Comments

Steve Clemmons, president of VitaLink Research, commented that the sponsor “chose our groups as well as South Carolina to be the places for this study because its already considered to be one of the hot spots in the southeast.” Clemons reported that the Phase 3 trial would commence “around mid-July” and that the whole study would consist of 30,000 participants. He reported that VitaLink planned to recruit 1,500 of the total participants via “upstate” South Carolina.

Moderna mRNA-1273 Study

Although VitaLink didn’t announce the name of the pharmaceutical sponsor, TrialSite News can report that this sponsor is, in fact, Moderna. The Massachusetts-based biotech has already disclosed that its randomized and placebo-controlled Phase III mRNA-1273 vaccine study, targeting 30,000 participants, would commence in July. Th...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee